These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28296710)

  • 21. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
    Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of concurrent chemotherapy to intensity-modulated radiotherapy (IMRT) after neoadjuvant docetaxel and cisplatin treatment in locoregionally advanced nasopharyngeal carcinoma.
    Zhang L; Shan GP; Li P; Cheng PJ
    Med Oncol; 2015 Mar; 32(3):41. PubMed ID: 25631634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
    Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
    Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic myeloid leukemia following the treatment of nasopharyngeal carcinoma.
    Kassar O; Mseddi S; Mdhaffer M; Bellaaj H; Mnif S; Ghorbel M; Sennena H; Elloumi M
    Tunis Med; 2017 Mar; 95(3):222. PubMed ID: 29446820
    [No Abstract]   [Full Text] [Related]  

  • 25. [Efficacy of Yanshu injection (a compound Chinese traditional medicine) combined with concurrent radiochemotherapy in patients with stage III nasopharyngeal carcinoma].
    Wei R; Yang DY; Jiang WZ; Dai YY; Wan LY; Yang Z
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):391-4. PubMed ID: 21875474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
    JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.
    Guan Y; Liu S; Wang HY; Guo Y; Xiao WW; Chen CY; Zhao C; Lu TX; Han F
    Chin J Cancer; 2016 Feb; 35():20. PubMed ID: 26879049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution and Management of Treatment-Related Toxicity in Anal Cancer.
    Ludmir EB; Kachnic LA; Czito BG
    Surg Oncol Clin N Am; 2017 Jan; 26(1):91-113. PubMed ID: 27889040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy.
    Pan JJ; Ng WT; Zong JF; Chan LL; O'Sullivan B; Lin SJ; Sze HC; Chen YB; Choi HC; Guo QJ; Kan WK; Xiao YP; Wei X; Le QT; Glastonbury CM; Colevas AD; Weber RS; Shah JP; Lee AW
    Cancer; 2016 Feb; 122(4):546-58. PubMed ID: 26588425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A comparative study of long-term effects between induction chemotherapy and concurrent chemotherapy on patients with local advanced nasopharyngeal carcinoma].
    Wang HB; Chen Y
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(5):361-365. PubMed ID: 29871262
    [No Abstract]   [Full Text] [Related]  

  • 35. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
    Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
    Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of clinical practice guideline for nasopharyngeal and oropharyngeal cancer to reduce acute treatment toxicity from concurrent chemoradiation.
    Suntornpong N; Sukkasem M; Uwattanasombat C; Samasanti N; Thephamongkol K
    J Med Assoc Thai; 2011 May; 94(5):585-91. PubMed ID: 21675449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Childhood Nasopharyngeal Carcinoma: State-of-the-Art, and Questions for the Future.
    Dourthe ME; Bolle S; Temam S; Jouin A; Claude L; Reguerre Y; Defachelles AS; Orbach D; Fresneau B
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):85-92. PubMed ID: 29300240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Retrospective analysis of effectiveness of intensity-modulated radiotherapy combined with chemotherapy or not for locoregionally advanced nasopharyngeal carcinoma].
    He F; Luo W; Zhang Q; Guo Y; Liu MZ; Ma J
    Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(29):2292-5. PubMed ID: 24300148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.